67 results
The primary objective is to prospectively assess whether a sequential approach with an induction period of 12 weeks with encorafenib + binimetinib followed by an immunotherapy combination with nivolumab + ipilimumab improves Progression Free…
*In the phase Ib study: to assess the feasibility and safety of the addition of nivolumab and/or ipilimumab to MMC/capecitabine chemoradiation of the bladder.*In the phase II study: to assess the impact of the addition of the addition of nivolumab…
Primary objectives: 1. Establish whether a sequenced pre-operative schedule of ipilimumab and nivolumab is safe in urothelial cancer patients (cohort 1)Secondary objectives: 2. Dissect the tumor micro-environment of urothelial cancers before and…
Primary Objectives• To compare the of OS rate at 12 months of Nivolumab combined with Ipilimumab to standard of care in patients with previously untreated and advanced non-clear cell RCC, Secondary Objectives• To compare the OS rate at 6 and 18…
Primary Objective:All lines1) To compare the BICR-assessed PFS of participants with centrally confirmed dMMR/MSI-H mCRC and randomized to nivolumab plus ipilimumab combination therapy arm or nivolumab monotherapy arm1L1) To compare the BICR-assessed…
• To evaluate the efficacy of treatment• To evaluate the safety of treatment
The study aims to demonstrate that treatment with nivolumab combined with ipilimumab will improve efficacy in cisplatin-ineligible participants with previously untreated unresectable or metastatic UC and also treatment with nivolumab combined with…